INTERVIEW: Zeus Capital Upgrade forecast for Allergy Therapeutics Plc

Allergy Therapeutics Plc (LON:AGY) is the topic of conversation when DirectorsTalk caught up with Dr Gary Waanders the Director of Healthcare Research at Zeus Capital. Gary explains whats driven growth in the 6 months to Dec 31st, affects on the full year and what other things should we be focusing on for Allergy Therapeutics.


Allergy Therapeutics Plc is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Formed in 1999 out of Smith Kline Beecham, the comapy is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.495 employees and is listed on the London Stock Exchange (LON:AGY).  The company had its target price increased by analysts at FinnCap on Thursday from GBX 40 to GBX 43. The firm currently has a “buy” rating on the stock, however a number of brokers have issued stock reports with the consensus target price being 64.67 GBX.

You might also enjoy reading  Allergy Therapeutics appoint Martin Hopcroft as Interim Chief Financial Officer
Find more news, interviews, share price & company profile here for:

You can also listen to our interviews on: 

Share this interview

Allergy Therapeutics plc
INTERVIEW: Zeus Capital Upgrade forecast for Allergy Therapeutics Plc

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions